Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
M&A can help revitalize firms but failure to properly integrate the companies can create an inefficient, demoralized business. In this article, Viq Pervaaz, senior vice president at Aon Consulting, takes a look at M&A processes, pitfalls and keys...
Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
India’s oldest pharmaceutical company Alembic went one step closer to the biggest restructuring in its history as its board approved the demerging of its main pharmaceutical business into a separate subsidiary company, Alembic Pharma.
Sosei has revealed its intention to acquire Activus Pharma in a deal which allows the Japan-based firm to get their hands on Activus' nanoparticle drug formulation tools, a technology that’s in its infancy but holds great potential.
A deal to broaden Gilead’s research expertise into protein kinase biology has been finalised with the $120m acquisition of CGI Pharmaceuticals, in a deal that compliments its comprehensive selection of anti-HIV treatments.